Evidence map›Paper›PMID 33736633›Full record

ArticleBMC endocrine disorders2021

Up-regulation of sex-determining region Y-box 9 (SOX9) in growth hormone-secreting pituitary adenomas.

Farzad Izak Shirian, Mohammad Ghorbani, Mohammad E Khamseh, Mehrnaz Imani, Mahshid Panahi, Alimohammad Alimohammadi, Mitra Nourbakhsh, Vahid Salimi, Masoumeh Tavakoli-Yaraki

Open access · goldAbstract read
In one paragraph

Article in BMC endocrine disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Farzad Izak ShirianDepartment of Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Mohammad GhorbaniEndocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IUMS), Tehran, Iran. ghorbani.m@iums.ac.ir.
Mohammad E KhamsehEndocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Mehrnaz ImaniEndocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Mahshid PanahiFirozgar Hospital, Pathology Department, Iran University of Medical Sciences, Tehran, Iran.
Alimohammad AlimohammadiIranian Legal Medicine Organizations, Tehran, Iran.
Mitra NourbakhshDepartment of Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Vahid SalimiDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Masoumeh Tavakoli-YarakiDepartment of Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. tavakoli.m@iums.ac.ir.ORCID https://orcid.org/0000-0003-4449-9248
Iran University of Medical Sciences · IRIranian Legal Medicine Organization · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPituitary adenomas are benign brain tumors that cause considerable morbidity and neurological symptoms. SOX9 as a regulatory transcriptional mediator affects normal and tumor cell growth with an undefined role in pituitary adenomas pathogenesis. Thus, in the present study, the expression pattern of SOX9 in GH-secreting pituitary tumors and normal pituitary tissues is investigated.

methodsThe SOX9 gene expression level was evaluated in 60 pituitary tissues including different types of GH-secreting adenomas and normal pituitary tissues through Real-Time PCR. The protein level of SOX9 was assessed using immunohistochemistry. The correlations of SOX9 gene and protein expression level with the patient's clinical and pathological features were considered.

resultsThe SOX9 over-expression was detected in GH-secreting adenomas tumor tissues compared to normal pituitary tissues which were accompanied by overexpression of SOX9 protein in tumor tissues. The over-expression of SOX9 had a significant impact on GH-secreting adenomas tumor incidence with the odds ratio of 8.4 and the diagnostic value of SOX9 was considerable. The higher level of SOX9 expression was associated with invasive and macro tumors in GH-secreting pituitary adenoma patients. The positive correlation of SOX9 gene and protein level was observed and the tumor size and tumor invasive features were valuable in predicting SOX9 expression level in GH-producing pituitary tumors.

conclusionThe study provided the first shreds of evidence regarding the expression pattern of SOX9 in the GH- secreting pituitary adenomas at both gene and protein levels which may emphasize the possible involvement of SOX9 as a mediator in pituitary adenoma tumor formation also open up new intrinsic molecular mechanism regarding pituitary adenoma pathogenesis.

Indexed as

AcromegalyAdenomaAdultAgedCase-Control StudiesFemaleGene Expression Regulation, NeoplasticGrowth Hormone-Secreting Pituitary AdenomaHumansImmunohistochemistryMaleMiddle AgedRNA, MessengerSOX9 Transcription FactorUp-RegulationRNA, MessengerSOX9 protein, humanSOX9 Transcription FactorGrowth hormone -pituitary adenomaInvasive tumorsMacroadenomaMicroadenomaSOX9

Identifiers

PMID33736633
PMCPMC7971953
OpenAlexW3138102087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.